Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9056 formulation Phase III · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 50 or 400 mg AZD9056, Test formulation |
| 2 | EXPERIMENTAL | 50 or 400 mg AZD9056, Reference formulation |
| Name | Type | Description |
|---|---|---|
| AZD9056 formulation Phase III 50 mg (T) | DRUG | Given as 50 mg tablet (T) |
| AZD9056 formulation Phase IIb 50 mg (R) | DRUG | Given as 50 mg tablet (R) |
| AZD9056 formulation Phase III 200 mg (T) | DRUG | Given as 400 mg (2 x 200 mg tablet (T)) |
| AZD9056 formulation Phase IIb 200mg (R) | DRUG | Given as 400 mg (2 x 200 mg tablet (R)) |
Inclusion Criteria: * Provision of informed consent prior to any study-specific procedures * Healthy Volunteers, Females should not be of childbearing potential * BMI between 18 and 30 kg/m2 Exclusion Criteria: * Clinically significant ECG abnormality suggestive of underlying cardiovascular disea...
AZD9056 formulation Phase III is an investigational small molecule developed by AstraZeneca PLC. It is a P2RX7 antagonist that has been studied in a Phase 1 relative bioavailability trial in healthy volunteers. The formulation designation refers to a specific version of the drug evaluated in that study.
AZD9056 formulation Phase III targets P2RX7, a purinergic receptor. It acts as an antagonist at this target. The molecular target is P2RX7, and the compound is classified as a small molecule P2RX7 antagonist.
AstraZeneca PLC is developing AZD9056 formulation Phase III. The company's ticker symbol is AZN. AstraZeneca is the sponsor of the clinical trial evaluating this drug.
AZD9056 formulation Phase III is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The only listed trial is a completed Phase 1 study.
AZD9056 formulation Phase III has been studied in one clinical trial: NCT00908934, titled AZD9056 Relative Bioavailability Study. This Phase 1 trial was completed, enrolled 24 healthy volunteers, and was conducted in the United Kingdom. It was randomized and controlled but not double-blind.